CMPS Share Price Performance
US$9.46
6.08 (179.88%)
56.8% undervalued intrinsic discount
US$21.92
Fair Value
Price US$9.46
AnalystConsensusTarget US$21.92
AnalystHighTarget US$52.55
AnalystLowTarget US$8.00
Fair ValueUS$21.92
Share Pricen/a
COMPASS Pathways plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 41 Fair Values set on narratives written by author
CMPS Community Narratives
AN
Fair Value US$21.92 56.8% undervalued intrinsic discount
Phase III Completion And PTSD Expansion Will Support A Durable Mental Health Franchise
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$52.55 82.0% undervalued intrinsic discount
Phase III Progress And PTSD Expansion Will Reshape Long Term Psychedelic Mental Health Treatment
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$8 18.3% overvalued intrinsic discount
Phase III Trial Dependence Will Dominate Near Term While Long Term Potential Remains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Phase III Progress And PTSD Expansion Will Reshape Long Term Psychedelic Mental Health Treatment
Catalysts About COMPASS Pathways COMPASS Pathways is a mental health company developing COMP360 psilocybin treatment for conditions such as treatment resistant depression and PTSD. What are the underlying business or industry changes driving this perspective?Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$52.55
82.0% undervalued intrinsic discount
Fair Value
Profit Margin
36.21%
Future PE
42.58x
Price in 2029
US$0
Phase III Completion And PTSD Expansion Will Support A Durable Mental Health Franchise
Catalysts About COMPASS Pathways COMPASS Pathways is a mental health company developing COMP360 psilocybin treatment for conditions such as treatment resistant depression and PTSD. What are the underlying business or industry changes driving this perspective?Read more
33
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$21.92
56.8% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
117.36x
Price in 2029
US$0
Phase III Trial Dependence Will Dominate Near Term While Long Term Potential Remains
Catalysts About COMPASS Pathways COMPASS Pathways is a mental health company developing COMP360, a psilocybin-based treatment for conditions such as treatment resistant depression and PTSD. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$8
18.3% overvalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
159.46x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Phase III Progress And PTSD Expansion Will Reshape Long Term Psychedelic Mental Health Treatment
Fair Value: US$52.55 82.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Phase III Completion And PTSD Expansion Will Support A Durable Mental Health Franchise
Fair Value: US$21.92 56.8% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Phase III Trial Dependence Will Dominate Near Term While Long Term Potential Remains
Fair Value: US$8 18.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
COMPASS Pathways plc Key Details
About CMPS
- Founded
- 2020
- Employees
- 156
- CEO
- WebsiteView website
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
